Igene Biotechnology, Inc.
IGNE
$0.00
$0.000.00%
OTC PK
| 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | 09/30/2009 | |
|---|---|---|---|---|---|
| Revenue | -99.91% | -81.18% | -54.84% | -48.23% | -37.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.91% | -81.18% | -54.84% | -48.23% | -37.59% |
| Cost of Revenue | -100.79% | -91.99% | -59.84% | -53.99% | -30.22% |
| Gross Profit | -94.85% | 8.66% | -31.01% | -18.73% | -61.13% |
| SG&A Expenses | -38.12% | -34.02% | -34.41% | -29.73% | -6.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -53.76% | -163.83% | -377.22% | -- | -990.14% |
| Total Operating Expenses | -90.51% | -86.49% | -64.99% | -59.63% | -32.97% |
| Operating Income | 40.38% | 103.87% | 96.26% | 99.49% | -10.68% |
| Income Before Tax | -105.19% | 21.18% | 41.31% | 95.57% | 62.02% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -105.19% | 21.18% | 41.31% | 95.57% | 62.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.19% | 21.18% | 41.31% | 95.57% | 62.02% |
| EBIT | 40.38% | 103.87% | 96.26% | 99.49% | -10.68% |
| EBITDA | 38.32% | 116.37% | 106.51% | 109.37% | -0.42% |
| EPS Basic | 51.61% | 90.38% | 95.19% | 100.00% | 88.77% |
| Normalized Basic EPS | 56.52% | 89.71% | 95.00% | 97.02% | 86.63% |
| EPS Diluted | 51.61% | 90.38% | 95.19% | 100.00% | 88.77% |
| Normalized Diluted EPS | 56.52% | 89.71% | 95.00% | 97.02% | 86.63% |
| Average Basic Shares Outstanding | 24.88% | 75.11% | 187.30% | 722.13% | 1,033.69% |
| Average Diluted Shares Outstanding | 24.88% | 75.11% | 187.30% | 722.13% | 1,033.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |